Cardiac toxicity of anticancer agents

Area of Science:

• Cardiology
• Oncology
• Pharmacology

Background:

• Cancer therapies, including conventional and targeted agents, can cause cardiotoxicity, primarily manifesting as left ventricular dysfunction.
• Current monitoring methods like left ventricular ejection fraction assessment detect cardiotoxicity late, limiting preventative interventions.
• Cardiac biomarkers offer a novel, cost-effective tool for early, real-time cardiotoxicity detection and monitoring.

Purpose of the Study:

• To highlight the significance of cardiac biomarkers in the early detection of cardiotoxicity.
• To emphasize the effectiveness of early intervention with medications like enalapril in preventing left ventricular dysfunction.
• To discuss the benefits of prompt treatment with ACE inhibitors and beta-blockers for cancer treatment-induced cardiomyopathy.

Main Methods:

• Review of current literature on cancer therapy-induced cardiotoxicity.
• Analysis of the role of cardiac biomarkers (e.g., troponin) in early detection.
• Evaluation of prophylactic and therapeutic strategies for managing cardiotoxicity.

Main Results:

• Early increases in troponin levels after chemotherapy predict cardiotoxicity.
• Prophylactic enalapril treatment in patients with elevated troponin can prevent left ventricular dysfunction.
• Prompt initiation of ACE inhibitors, potentially with beta-blockers, improves left ventricular ejection fraction recovery and reduces cardiac events.

Conclusions:

• Cardiac biomarkers are crucial for the early identification and management of cardiotoxicity.
• Timely intervention with specific medications can mitigate or reverse cardiac damage caused by cancer treatments.
• An integrated approach combining early biomarker monitoring and prompt pharmacotherapy is essential for preserving cardiac function in cancer patients.